MICRO RNAS IN HIGH-GRADE GLIOMAS: WHAT IS THEIR ROLE?
Abstract
High-grade gliomas are malignant tumours of the central nervous system with poor overall survival. Equivalently, glioblastoma is one of the most devastating brain tumours. Treatment for most high-grade gliomas includes surgical resection, radiotherapy, and chemotherapy. Even with all treatment modalities, at a certain point, disease progression occurs. Moreover, each of the treatment modalities can lead to different toxicities. In the last ten years, many studies have aimed to find a stable and unique biomarker that can help diagnose brain tumours, overcome treatment resistance, and improve overall survival. MicroRNAs are non-coding elements of the genome that are relatively stable in serum and plasma and can be isolated from the tissue as well. It has been discovered that the alteration of many microRNAs can be seen in high-grade gliomas. The determined microRNA could potentially play a part in the diagnosis and prognosis of high-grade gliomas, have a therapeutic role in the treatment of high-grade gliomas or act as a predictive biomarker of treatment-induced toxicity. To achieve this, every high-grade glioma should have its own microRNA signature. Numerous studies have detected a big potential of certain microRNAs. The disadvantages of these studies are that they mostly included a small number of samples. Moreover, research into microRNA as potential therapeutic agents has primarily been based on cell lines, or xenografts. On the other hand, many microRNAs show significant alterations in high-grade gliomas, but still, their altered expression can be detected in other cancers and some non-oncological diseases. In this article, we made a critical mini-review of the role of microRNAs in high-grade gliomas.
References
1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
2. Stepanović A, Nikitović M, Bogdanović A, Grujičić D. Long-lasting Thrombocytopenia after Transient Pancytopenia Induced by Short-Term Concomitant Radiotherapy and Temozolomide. Eur J Case Rep Intern Med. 2020;7(10):001785.
3. Stepanovic A, Nikitovic M. Severe hematologic temozolomide-related toxicity and lifethreatening infections. J BUON. 2018;23(1):7–13.
4. Stepanović A, Arsenijevic T, Stankovic V, Vujanac V, Lazovic A, Raonic-Stevanovic T, et al. Clinical analysis of COVID-19 positive cancer inpatients in National Cancer Center in Serbia. J Infect Dev Ctries. 2021;15(09):1286–92.
5. Stepanovic A, Nikitovic M. Radiotherapy and COVID-19 pandemic - a review of the current recommendations. Srp Arh Celok Lek. 2020;148(9–10):644–7.
6. Petrovic N, Ergun S. miRNAs as Potential Treatment Targets and Treatment Options in Cancer. Mol Diagn Ther. 2018;22(2):157–68.
7. Dioguardi M, Caloro GA, Laino L, Alovisi M, Sovereto D, Crincoli V, et al. Circulating miR-21 as a Potential Biomarker for the Diagnosis of Oral Cancer: A Systematic Review with Meta-Analysis. Cancers. 2020;12(4):936.
8. Mahmood N, Hanif M, Ahmed A, Jamal Q, Mushtaq S, Khan A, et al. Circulating miR-21 as a prognostic and predictive biomarker in oral squamous cell carcinoma. Pak J Med Sci. 2019;35(5):1408-1412.
9. Jiang G, Mu J, Liu X, Peng X, Zhong F, Yuan W, et al. Prognostic value of miR-21 in gliomas: comprehensive study based on meta-analysis and TCGA dataset validation. Sci Rep. 2020;10(1):4220.
10. Wu L, Li G, Feng D, Qin H, Gong L, Zhang J, et al. MicroRNA-21 expression is associated with overall survival in patients with glioma. Diagn Pathol. 2013;8(1):200.
11. Masoudi MS, Mehrabian E, Mirzaei H. MiR‐21: A key player in glioblastoma pathogenesis. J of Cellular Biochemistry. 2018;119(2):1285–90.
12. Zhou W, Su L, Duan X, Chen X, Hays A, Upadhyayula S, et al. MicroRNA-21 down-regulates inflammation and inhibits periodontitis. Molecular Immunology. 2018;101:608–14.
13. Ozdogan S, Yaltirik CK, Yilmaz SG, Akdeniz FT, Sumerkent K, Duzkalir AH, et al. Investigation of the Effects of MicroRNA-221 Expression Levels in Glioblastoma Multiforme Tumors. Anticancer Res. 2020;40(6):3265–70.
14. Regazzo G, Terrenato I, Spagnuolo M, Carosi M, Cognetti G, Cicchillitti L, et al. A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomas. J Exp Clin Cancer Res. 2016;35(1):124.
15. Parker NR, Correia N, Crossley B, Buckland ME, Howell VM, Wheeler HR. Correlation of MicroRNA 132 Up-regulation with an Unfavorable Clinical Outcome in Patients with Primary Glioblastoma Multiforme Treated with Radiotherapy Plus Concomitant and Adjuvant Temozolomide Chemotherapy. Translational Oncology. 2013;6(6):742-IN34.
16. Sasayama T, Nishihara M, Kondoh T, Hosoda K, Kohmura E. MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. Int J Cancer. 2009;125(6):1407–13.
17. Teplyuk NM, Uhlmann EJ, Gabriely G, Volfovsky N, Wang Y, Teng J, et al. Therapeutic potential of targeting micro RNA‐10b in established intracranial glioblastoma: first steps toward the clinic. EMBO Mol Med. 2016;8(3):268–87.
18. Guessous F, Alvarado-Velez M, Marcinkiewicz L, Zhang Y, Kim J, Heister S, et al. Oncogenic effects of miR-10b in glioblastoma stem cells. J Neurooncol. 2013;112(2):153–63.
19. Sun B, Zhao X, Ming J, Liu X, Liu D, Jiang C. Stepwise detection and evaluation reveal miR-10b and miR-222 as a remarkable prognostic pair for glioblastoma. Oncogene. 2019;38(33):6142–57.
20. Zurlo M, Romagnoli R, Oliva P, Gasparello J, Finotti A, Gambari R. Synergistic Effects of A Combined Treatment of Glioblastoma U251 Cells with An Anti-miR-10b-5p Molecule and An AntiCancer Agent Based on 1-(3′,4′,5′-Trimethoxyphenyl)-2-Aryl-1H-Imidazole Scaffold. IJMS. 2022;23(11):5991.
21. Chao TF, Xiong HH, Liu W, Chen Y, Zhang JX. MiR-21 mediates the radiation resistance of glioblastoma cells by regulating PDCD4 and hMSH2. J Huazhong Univ Sci Technolog Med Sci. 2013;33(4):525-529.
22. Xiao S, Yang Z, Lv R, Zhao J, Wu M, Liao Y, et al. miR-135b Contributes to the Radioresistance by Targeting GSK3β in Human Glioblastoma Multiforme Cells. Alonso MM, editor. PLoS ONE. 2014;9(9):e108810.
23. Yin J, Zeng A, Zhang Z, Shi Z, Yan W, You Y. Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma. EBioMedicine. 2019;42:238–51.
24. Starkey Lewis PJ, Dear J, Platt V, Simpson KJ, Craig DGN, Antoine DJ, et al. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology. 2011;54(5):1767–76.
25. Kopcalic K, Petrovic N, Stanojkovic TP, Stankovic V, Bukumiric Z, Roganovic J, et al. Association between miR-21/146a/155 level changes and acute genitourinary radiotoxicity in prostate cancer patients: A pilot study. Pathology - Research and Practice. 2019;215(4):626–31.
26. Stafford MYC, Willoughby CE, Walsh CP, McKenna DJ. Prognostic value of miR-21 for prostate cancer: a systematic review and meta-analysis. Bioscience Reports. 2022;42(1):BSR20211972.
27. Stanojković TP, Matić IZ, Petrović N, Stanković V, Kopčalić K, Besu I, et al. Evaluation of cytokine expression and circulating immune cell subsets as potential parameters of acute radiation toxicity in prostate cancer patients. Sci Rep. 2020;10(1):19002.
28. Stepanović A, Nikitović M, Stanojković TP, Grujičić D, Bukumirić Z, Srbljak I, et al. Association between microRNAs 10b/21/34a and acute toxicity in glioblastoma patients treated with radiotherapy and temozolomide. Sci Rep. 2022;12(1):7505.